+

SG10201808940WA - Nox inhibitor and nfкb inhibitor containing methoxyflavone - Google Patents

Nox inhibitor and nfкb inhibitor containing methoxyflavone

Info

Publication number
SG10201808940WA
SG10201808940WA SG10201808940WA SG10201808940WA SG10201808940WA SG 10201808940W A SG10201808940W A SG 10201808940WA SG 10201808940W A SG10201808940W A SG 10201808940WA SG 10201808940W A SG10201808940W A SG 10201808940WA SG 10201808940W A SG10201808940W A SG 10201808940WA
Authority
SG
Singapore
Prior art keywords
inhibitor
nox
nfкb
inhibitors
methoxyflavone
Prior art date
Application number
SG10201808940WA
Inventor
Daisuke Takemoto
Yoshiko Ono
Sumio Asami
Satomi Shimoyoshi
Original Assignee
Suntory Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd
Publication of SG10201808940WA publication Critical patent/SG10201808940WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)

Abstract

NOX INHIBITOR AND NFKB INHIBITOR CONTAINING METHOXYFLAVONE The present invention aims at providing NOX inhibitors and NFKB inhibitors having superior actions, as well as agents for preventing or treating NOX- or NFicB-associated diseases that utilize such inhibitors. To this end, specified methoxyflavones are employed.
SG10201808940WA 2014-05-09 2015-05-01 Nox inhibitor and nfкb inhibitor containing methoxyflavone SG10201808940WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014097875 2014-05-09

Publications (1)

Publication Number Publication Date
SG10201808940WA true SG10201808940WA (en) 2018-11-29

Family

ID=54392533

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201808940WA SG10201808940WA (en) 2014-05-09 2015-05-01 Nox inhibitor and nfкb inhibitor containing methoxyflavone
SG11201609248WA SG11201609248WA (en) 2014-05-09 2015-05-01 Nox inhibitor and nfκb inhibitor containing methoxyflavone

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201609248WA SG11201609248WA (en) 2014-05-09 2015-05-01 Nox inhibitor and nfκb inhibitor containing methoxyflavone

Country Status (9)

Country Link
US (1) US20170071902A1 (en)
JP (3) JP2015227329A (en)
KR (1) KR20170002565A (en)
CN (1) CN106456597A (en)
AU (1) AU2015256997B2 (en)
CA (1) CA2948127A1 (en)
SG (2) SG10201808940WA (en)
TW (1) TWI700278B (en)
WO (1) WO2015170683A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023144742A1 (en) 2022-01-26 2023-08-03 Universidade De Aveiro Ionic-liquid-based formulations for the prevention or treatment of neurological diseases

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017145221A (en) * 2016-02-18 2017-08-24 株式会社レーネ Tau protein aggregation inhibitor
JP6909559B2 (en) * 2016-03-31 2021-07-28 株式会社アンチエイジングコミュニケーション OPH activity enhancer
JP6462755B2 (en) * 2017-04-04 2019-01-30 丸善製薬株式会社 Brain function improving agent and food and drink for improving brain function
TWI646943B (en) * 2017-12-08 2019-01-11 財團法人自行車暨健康科技工業研究發展中心 Method for screening for muscular dysfunction through functional fitness
KR102032739B1 (en) * 2018-01-31 2019-10-16 한림대학교 산학협력단 Pharmaceutical composition for preventing and treating diabetic complications containing the novel chrysin derivative
CN110237066B (en) * 2018-03-07 2022-03-29 上海市生物医药技术研究院 Application of 3-methoxyflavone and derivatives thereof in preparation of medicines for treating or preventing nephropathy
CN108904489A (en) * 2018-06-19 2018-11-30 杭州勃锐思莫生物医药科技有限责任公司 The purposes of the preventing respiratory diseases associated with inflammation of 3,4 ' flavonol of 5,7- methoxyl group
JP7229513B2 (en) * 2018-10-16 2023-02-28 丸善製薬株式会社 Brain function improving agent and food and drink for improving brain function
JP2022509359A (en) 2018-10-26 2022-01-20 ガラニン、アイバン Topical compositions and methods for promoting optimal dermal white adipose tissue formation in vivo
CN109288834A (en) * 2018-11-28 2019-02-01 武汉科技大学 Application of 5-methoxyflavones in the preparation of nonsense mutation read-through drugs
WO2020178267A1 (en) * 2019-03-04 2020-09-10 Universite D'aix-Marseille Nox inhibitors for preventing epileptic seizures
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
CN110357846B (en) * 2019-07-11 2021-06-15 上海健康医学院 A kind of flavonoid and monoterpenoid compound and its preparation method and application
US20230021051A1 (en) * 2019-12-26 2023-01-19 Maruzen Pharmaceuticals Co., Ltd. Composition Containing Black Ginger Extract and Composition for Oral Administration
JP7467138B2 (en) * 2020-01-30 2024-04-15 株式会社 資生堂 Intestinal barrier improver
CN111374970B (en) * 2020-03-17 2023-05-30 广西壮族自治区中医药研究院 Composition with anti-colitis activity and application thereof
CN111617076B (en) * 2020-06-24 2021-09-28 江苏吴中医药集团有限公司 Compound pharmaceutical composition containing arbidol hydrochloride and application thereof
JP7081843B2 (en) * 2020-10-26 2022-06-07 株式会社東洋新薬 Autonomic nerve regulator
JPWO2022137964A1 (en) * 2020-12-23 2022-06-30
CN116650476B (en) * 2023-05-30 2025-09-09 南华大学附属第一医院 Compound, composition and application thereof in preparation of medicines for treating heart diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067507B2 (en) * 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
JP2007314468A (en) * 2006-05-25 2007-12-06 Meiji Milk Prod Co Ltd Endoplasmic reticulum stress control compound and pharmaceutical composition comprising the same
JP2009051790A (en) * 2007-08-29 2009-03-12 Maruzen Pharmaceut Co Ltd Antioxidant, anti-aging agent, anti-inflammatory agent, hair restoration agent, anti-obesity agent, skin-lightening agent, cosmetic and food and drink for cosmetic use
JP5756264B2 (en) * 2010-05-06 2015-07-29 日本タブレット株式会社 Xanthine oxidase inhibitor, xanthine oxidase and 5α-reductase inhibitor, and pharmaceutical composition containing the inhibitor
KR101811303B1 (en) * 2011-07-26 2017-12-26 에스케이하이닉스 주식회사 Semiconductor integrated circuit and method of driving the same
EP2799081A4 (en) * 2011-12-27 2015-06-24 Tokiwa Phytochemical Co Ltd SIRTUIN ACTIVATOR
JP2013144659A (en) * 2012-01-16 2013-07-25 Nippon Tablet Kk 5α-REDUCTASE INHIBITOR AND FOOD, DRINK, COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING THE INHIBITOR
KR101528023B1 (en) * 2012-05-16 2015-06-15 연세대학교 산학협력단 Composition for prevention and treatment of muscular disorder or improvement of muscular functions comprising Kaempferia parviflora extract or flavone compounds
JP2013241354A (en) * 2012-05-18 2013-12-05 Oriza Yuka Kk Phosphodiesterase 2 inhibitor
JP2013253047A (en) * 2012-06-07 2013-12-19 Kinki Univ Hemorheology improving agent, and food and drink and pharmaceutical composition including the same
WO2013185301A1 (en) * 2012-06-13 2013-12-19 Jin Yongri Use of flavone and flavanone derivatives in preparation of sedative and hypnotic drugs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023144742A1 (en) 2022-01-26 2023-08-03 Universidade De Aveiro Ionic-liquid-based formulations for the prevention or treatment of neurological diseases

Also Published As

Publication number Publication date
KR20170002565A (en) 2017-01-06
CN106456597A (en) 2017-02-22
AU2015256997A1 (en) 2016-11-24
JP2015227329A (en) 2015-12-17
JP2020063283A (en) 2020-04-23
SG11201609248WA (en) 2016-12-29
TWI700278B (en) 2020-08-01
WO2015170683A1 (en) 2015-11-12
AU2015256997B2 (en) 2020-07-09
JP6666837B2 (en) 2020-03-18
CA2948127A1 (en) 2015-11-12
US20170071902A1 (en) 2017-03-16
JPWO2015170683A1 (en) 2017-04-20
TW201625574A (en) 2016-07-16
JP7015822B2 (en) 2022-02-15

Similar Documents

Publication Publication Date Title
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
CY1124215T1 (en) MK2 INHIBITORS AND THEIR USES
MX2022009148A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES.
MX2019003623A (en) Compositions and methods for treating ophthalmic conditions.
MX379270B (en) COMPOSITIONS INCLUDING BACTERIAL STRAINS.
MX2015008999A (en) Mk2 inhibitors and uses thereof.
MX2018009773A (en) Heteroaryl inhibitors of pad4.
MX2016003843A (en) Irak inhibitors and uses thereof.
MX2018006632A (en) Bicyclic inhibitors of pad4.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
MX2018006700A (en) Aza-benzimidazole inhibitors of pad4.
GB2541571A (en) Pharmaceutical compositions
MX2018009325A (en) Compounds and methods of treating rna-mediated diseases.
EA033325B1 (en) Bromodomain inhibitors
MX2017004510A (en) Triazolopyrazinones as pde1 inhibitors.
EA201591278A1 (en) COMPOSITIONS CONTAINING C1-INH, AND METHODS OF PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH THE DEFICIENCY C1 inhibitor
EA201891340A1 (en) CANCER TREATMENT USING 2-DEOXY-2-FLUOR-L-FUKOZA IN COMBINATION WITH CONTROLLER INHIBITOR INHIBITOR
MX376201B (en) METALLOENZYME INHIBITING COMPOUNDS.
EA201792604A1 (en) AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS
MX2017004808A (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis.
MX2021006326A (en) Pcna inhibitors.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2018000715A (en) Methods for treating cancer using apilimod.
MA40457A (en) Drug combinations to treat multiple myeloma
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载